Summary
June 2008, Vol. 9, No. 9, Pages 1509-1518
(doi:10.1517/14656566.9.9.1509)

Pharmacotherapy of kidney stones
Charles YC Pak
University of Texas Southwestern Medical Center, Center for Mineral Metabolism and Clinical Research, 5323 Harry Hines Boulevard, Dallas, TX 75390-8885, USA +1 214 648 0395; +1 214 648 0371;



Background: Kidney stones are associated with various biochemical disturbances in urine. Various drugs and dietary changes have been recommended to halt stone recurrence. Objective: To determine whether a correction of urinary abnormalities by appropriate pharmacological agents and dietary modification may ameliorate stone disease. Methods: A review of the literature was conducted on the role of diet, metabolic disorders and drugs for stone prevention. Results/conclusion: Metabolic risk factors are hypercalciuria, hypocitraturia, hyperoxaluria, hyperuricosuria, and abnormally low urinary pH. Dietary–environmental risk factors include high urinary sodium and low urine volume. Rare or less commonly encountered risk factors are high urinary cystine, and alkaline urine from an infection with urea-splitting organisms. To ameliorate or correct the above disturbances, all patients should be offered dietary modification, including restricted intake of sodium, oxalate and animal proteins. Useful drugs include thiazide or indapamide to control hypercalciuria, potassium citrate to correct hypocitraturia and undue urinary acidity, and allopurinol for co-existing hyperuricemia or marked hyperuricosuria.

Full Text | PDF (211 KB) | PDF Plus (229 KB)
 

Prev. Article | Next Article
View/Print PDF (211 KB)
View PDF Plus (229 KB)
Add to favourite
Email to a friend
TOC Alert | Citation Alert What is RSS?

Quick Links
 • Alert me when:
New articles cite this article
 • Download to citation manager
 • Related articles found in:
Expert Opinion series
 • View Most Downloaded Articles
 
 
Quick Search
for 
Author:
Charles YC Pak
Keywords:
hypercalciuria
hyperoxaluria
potassium citrate
renal stone